MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on inflammatory diseases, notably hidradenitis suppurativa and psoriatic arthritis, built around its lead asset sonelokimab, a nanobody targeting IL-17A and IL-17F licensed from AstraZeneca. The company went public through a business combination with Helixa Acquisition Corp (Nasdaq: HLXA), a healthcare-focused special purpose acquisition company that completed its IPO in 2021 and filed its S-1 registration statement for the merger on February 11, 2022. Following the transaction close, MoonLake began trading on Nasdaq under the ticker MLTX. Headquartered in Zug, Switzerland, MoonLake operates in the specialty biopharmaceutical sector with a pipeline targeting autoimmune and inflammatory conditions. Sign up at SpacDesk for full filing history, deal timelines, and sponsor data on this and hundreds of other SPAC transactions.